U.S. Women’s Health Market Size to Reach USD 34.53 Bn By 2033
Shivani Mhatre
???????????????????? | ?????????????????????????????? | ?????????????? ?????????????? & ???????????????? | ?????????????????????? ?????? ?????????????? | ???????? ????????????????
According to latest report, the U.S. Women’s Health market size was USD 23.19 billion in 2023, calculated at USD 24.13 billion in 2024 and is expected to reach around USD 34.53 billion by 2033, expanding at a CAGR of 4.06% from 2024 to 2033.
Full Report is Ready | Ask here for Sample Copy@ https://www.novaoneadvisor.com/report/sample/8325
The Market growth can be attributed to the increasing geriatric women population, the growing prevalence of targeted diseases, such as osteoporosis, osteoarthritis, and menstrual health, and the introduction of novel medicines for women’s health. Furthermore, favorable policies by governments to improve women’s health and raise awareness are likely to drive the market during the forecast period.
In addition, permanent ovarian failure due to genetic changes, such as sex chromosome abnormalities, can cause premature menopause in approximately 1% of women aged below 40 years in the U.S. The majority of women use supplements and over-the-counter medicine brands, such as Midol, Advil, Aleve, Motrin, Pamprin, Tylenol, and Cora, to manage pain due to menopause. Thus, increasing awareness about the benefits of these OTC drugs and supplements to manage symptoms is expected to impact market growth positively. Additionally, with over 4 million live births being reported each year in the U.S., this corresponds to almost 600,000 PPD diagnoses. Several women who miscarry or have stillbirths experience PPD symptoms as well, including women who have miscarried or have had a stillbirth. In the U.S., around 900,000 women suffer from PPD annually.
Contraceptives play an important role in preventing unwanted pregnancies. Currently, there are no OTC pills available in the U.S. for controlling pregnancy. Thus, introducing OTC contraceptive pills in the U.S. is expected to contribute to market growth positively. For instance, in July 2022, HRA Pharma submitted its application to the U.S. FDA for Rx-to-OTC change for the Opill contraceptives for women. The successful approval of Opill can make it the first birth control contraceptive to be available OTC without prescription in the U.S. Thus, the wide availability of OTC contraceptives and vitamin supplements, such as One A Day Women’s Prenatal 1, Nature Made Prenatal Multi, Rainbow Light Prenatal One, & Vitamin Code Raw, is anticipated to drive the women’s health market over the forecast period.
Governments and private organizations across the globe are increasing their focus on women’s health, which is likely to drive the market over the forecast period. In developed economies, coverage provided to women is one of the key factors expected to drive the market. For instance, various coverage plans in the U.S. provide preventive services for women without copayment charges, which include folic acid supplements for women trying to get pregnant, contraceptives, and screening for breast cancer, anemia, & hepatitis B. In the U.S., the Department of Health and Human Services established Healthy People 2020, aimed at improving U.S. individuals' health over the decade.
U.S. Women’s Health Market Key Takeaways
Buy Now Full Report: https://www.novaoneadvisor.com/report/checkout/8325
U.S. Women’s Health Market By Application Insights
The contraceptives segment held the highest revenue share of more than 36.16% of the Market revenue in 2023 due to the increase in Research & Development (R&D) activities and rising awareness about family planning among newly married people. For instance, researchers at the University of California recently developed a new drug that may replace daily contraceptive pills. Moreover, the rising support of major medical organizations, including the American College of Obstetricians & Gynecologists, the American Medical Association, and the Society for Adolescent Health & Medicine, and the American Academy of Family Physicians, to OTC oral contraception is also expected to drive segment growth.
The menopause segment is expected to grow at the highest CAGR rate over the forecast period. The growth can be attributed to the rising women population with menopause condition and the growing demand for its treatment. It is expected that every year, around 25 million women experience menopause globally, and by 2030, the total menopausal population is expected to be around 1.2 billion. In addition, about 75% of menopausal women experienced vasomotor symptoms and/or vaginal dryness. It can also lead to fluctuating estrogen levels, which is associated with various health conditions such as musculoskeletal health depletion and dementia. All these factors are expected to propel market growth over the forecast period.
U.S. Women’s Health Market By Drug Insights
The Prolia segment led the market in 2023, with a share of 20.32%, and is expected to grow at the fastest growth rate over the forecast period. Bone health issues and osteoporosis are different for women and young girls of various ethnic and ages backgrounds. Elder and Caucasian women who live in the U.S. are at high risk of developing osteoporosis due to lactose intolerant nature. According to the Bone Health and Osteoporosis, approximately 80% or 80 million women population suffer from osteoporosis in America. Women with small & thin bones and a decrease in estrogen levels are key possible reasons for high osteoporosis in women. Thus, the rising women population and the awareness about the benefits of treating with Prolia to cure disease is anticipated to boost segment growth over the forecast period.
XGEVA segment is expected to grow at a lucrative growth rate over the forecast period. This can be attributed to supportive reimbursement policies for XGEVA for the treatment of women with bone disease in the U.S. Currently, people with need of XGEVA for disease can get drugs at low cost through available co-pay or insurance coverage programs, such as prescription discount programs, Amgen SupportPlus Co-Pay Program, and NeedyMeds for U.S. people. These programs offer drugs at low cost to required patients and help address unmet market demand and drive segment growth.
U.S. Women’s Health Market By Age segment Insights
The other segment held a considerable market share of 60.09% in 2023. This can be attributed to the rising population of women below the age of 50 years. Women aged below 50 years are mainly in the reproductive age, and women’s health issues associated with this age group are more likely related to fertility, such as hormonal infertility, endometriosis, and PCOS. In the U.S., about 30% of menstruating women, along with 42% of young & pregnant women, were reported to be iron deficient, which can be attributed to monthly blood loss. This is expected to boost the demand for therapeutic drugs, thereby driving the market growth during the forecast period.
The 50-year-old & above-age segment is expected to register the fastest growth rate over the forecast period. Women aged 50 & above form the core demographic for the likelihood of menopause, and hence, the adoption of postmenopausal products is higher within this segment. According to the National Academy of Medical Science (NAMS) stated that every day in the U.S., an estimated 6,000 women reach menopause, which means over 2 million women reach menopause every year. All these factors are expected to drive the growth of this segment in the years to come.
U.S. Women’s Health Market Top Key Companies:
U.S. Women’s Health Market Recent Developments
领英推荐
U.S. Women’s Health Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Women’s Health market.
By Application?
By Drug?
50 years and above
Postmenopausal Osteoporosis
Endometriosis & Uterine Fibroids
Menopause
Others
Immediate Delivery Available | Buy This Premium Research
Procure Complete Report (220+ Pages PDF with Insights, Charts, Tables, and Figures) @ https://www.novaoneadvisor.com/report/checkout/8325
About Us
Nova One Advisor is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defines, among different ventures present globally.
Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |Europe: +44 2080772818
Email: [email protected]
?
?